CMHC presents one of the more unusual setups in European pharma right now: earnings momentum is running near multi-year highs while the stock has shed 10% over the past month and is down another 7% this week, sitting at CHF 56.90.
The disconnect between fundamentals and price is striking. ORTEX factor scores rank Cosmo's forward EPS momentum in the 91st percentile on a 12-month basis and the 94th percentile over 90 days — both readings point to consensus estimates that have been revised meaningfully higher in recent months. Yet the stock trades at a trailing PE of roughly 28x and an EV/EBITDA near 19.6x, both of which have compressed sharply: the PE multiple has fallen by more than 6 points in 30 days, and EV/EBITDA is down nearly 2 full turns. That combination — rising earnings estimates, falling valuation multiples — typically describes a market that has lost patience waiting for the fundamental improvement to show up in results. The most recent earnings print reinforced that anxiety: a day-one move of -0.47% followed by a five-day decline of 5.2%, consistent with the larger March event where the stock fell 7.7% on the day and 20% over the subsequent week.
The Street picture is difficult to assess cleanly. The available mean analyst price target of around CHF 131 implies substantial upside from current levels, but that data is dated enough to treat with caution — the most recent changes on record are over three weeks old, and the gap between the target and the current price is large enough that stale revisions could materially distort the figure. What is more reliable is the short score, which has climbed from around 29.9 at the start of August to 32.1 now — a steady, if modest, drift toward more bearish positioning over a period when the stock has been in freefall. The dividend score ranking (86th percentile) is a curiosity given that Cosmo's most recent dividend was issued in 2022, and the historical payout data appears stale.
The lending market continues to tell a different story from the price action. Availability has tightened meaningfully — down 32% over the past week to 1,843% of short interest — but 1,843% is still enormous by any measure, meaning there is no practical constraint on new short-sellers entering the stock. The 52-week minimum availability reading was 656%, so even the recent tightening leaves the borrow pool comfortably loose. Cost to borrow at 0.82% is up 7% this week but has been rangebound since late July and carries no urgency. This is not a market where shorts are being squeezed; it is one where they remain comfortably positioned at minimal cost.
Ownership adds a layer of context worth noting. Capital Research and Management disclosed a new 5.7% stake as of 30 June, a meaningful institutional arrival. Cassiopea SA and Heinrich Herz AG together account for more than 43% of shares, creating a concentrated register that limits float. Against that backdrop, the founder's April sales — 60,000 shares between CHF 98 and CHF 103, now roughly 40-45% above current levels — remain the most consequential insider signal on record, even at four months of age.
Peer context sharpens the picture. The closest correlated name, NWRN, gained 8.8% this week against CMHC's 7.3% decline. GSK and MRK both lost ground but only in the 0.4-2.3% range — far less severe. The divergence from even loosely correlated names suggests the selling in Cosmo is stock-specific rather than driven by sector headwinds.
What to watch is whether the Q2 earnings note published on July 23 — flat on the day but down 5% over five days — marks the beginning of a fresh leg lower or whether the improving EPS momentum score eventually finds traction with buyers willing to look through the multiple compression.
See the live data behind this article on ORTEX.
Open CMHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
